Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Reitmann C, Jumes P, Wolford D, Fraser I, Valesky R, Martinho M, Butterton JR, Iwamoto M, Webster L, Yeh WW. Feng HP, et al. Among authors: marshall wl. Clin Transl Sci. 2018 Nov;11(6):553-561. doi: 10.1111/cts.12564. Epub 2018 Jul 24. Clin Transl Sci. 2018. PMID: 30040872 Free PMC article. Clinical Trial.
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Feng HP, Guo Z, Caro L, Talaty JE, Mangin E, Panebianco D, Fandozzi C, Zhu Y, Marshall W, Huang X, Hanley WD, Jumes P, Valesky R, Martinho M, Butterton JR, Iwamoto M, Yeh WW. Feng HP, et al. Clin Pharmacol Drug Dev. 2019 Oct;8(7):962-970. doi: 10.1002/cpdd.701. Epub 2019 Jun 7. Clin Pharmacol Drug Dev. 2019. PMID: 31173674 Clinical Trial.
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O'Reilly TE, Butterton JR, Yeh WW. Marshall WL, et al. Eur J Clin Pharmacol. 2017 May;73(5):593-600. doi: 10.1007/s00228-017-2216-4. Epub 2017 Feb 24. Eur J Clin Pharmacol. 2017. PMID: 28233047
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton JR, Iwamoto M, Fraser I, Webster L, Yeh WW. Feng HP, et al. Among authors: marshall wl. Clin Transl Sci. 2018 Nov;11(6):562-572. doi: 10.1111/cts.12565. Epub 2018 Jul 24. Clin Transl Sci. 2018. PMID: 30040871 Free PMC article. Clinical Trial.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. Feng HP, et al. Among authors: marshall wl. J Antimicrob Chemother. 2019 Mar 1;74(3):710-717. doi: 10.1093/jac/dky465. J Antimicrob Chemother. 2019. PMID: 30541077 Clinical Trial.
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW. Feng HP, et al. Among authors: marshall wl. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02142-18. doi: 10.1128/AAC.02142-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745392 Free PMC article. Clinical Trial.
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY. Liu R, et al. Among authors: marshall wl. Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9. doi: 10.1128/AAC.01390-15. Epub 2015 Aug 24. Antimicrob Agents Chemother. 2015. PMID: 26303801 Free PMC article. Clinical Trial.
121 results